TCRT Insider Trading
Insider Ownership Percentage: 5.11%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Alaunos Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Alaunos Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Alaunos Therapeutics Share Price & Price History
Current Price: $1.78
Price Change: ▲ Price Increase of +0.05 (2.89%)
As of 01/17/2025 04:58 PM ET
Alaunos Therapeutics Insider Trading History
Alaunos Therapeutics Institutional Trading History
Data available starting January 2016
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
Read More on Alaunos Therapeutics
Volume
18,974 shs
Average Volume
24,775 shs
Market Capitalization
$2.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Alaunos Therapeutics?